Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancer Journal Article
| Authors: | Kindler, H. L.; Kris, M. G.; Smith, I. E.; Miller, V. A.; Grant, S. C.; Krebs, J. B.; Ross, G. A.; Slevin, M. L. |
| Article Title: | Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancer |
| Abstract: | Topotecan (9-dimethylaminoethyl-10-hydroxycamptothecin) is a topoisomerase I inhibitor. Twenty-six patients with stage IIIB or IV non- small-cell lung cancer (NSCLC) who had received no prior chemotherapy were treated in a multicenter study with topotecan 0.6 mg/m2/day for 21 days by continuous intravenous infusion every 28 days; this starting dose was decreased to 0.5 mg/m2/day in the last 23 patients because of myelosuppression. There was one partial response, for a response rate of 4% (95% confidence interval, 0.1%-19.6%). Median survival was 9 months. One- year survival was 39%. Of the 58 lung cancer symptoms at baseline, 40% were resolved by the end of best response (all in the partial response patient, 62% in stable disease patients, 26% in progressive disease patients). Catheter-related infections complicated 19% of courses. Red-cell transfusions were given in 50% of courses. Toxicity included grade 4 neutropenia (4%), grade 3-4 anemia (19%), grade 4 thrombocytopenia (8%), and catheter-related infections (19% courses). Although the major objective response rate was only 4%, patients treated with topotecan given as a 21-day continuous intravenous infusion experienced a decrease in cancer-related symptoms and a 1-year survival of 39%. |
| Keywords: | adult; cancer survival; clinical article; human tissue; aged; middle aged; survival analysis; human cell; clinical trial; neutropenia; antineoplastic agents; topotecan; cancer staging; neoplasm staging; phase 2 clinical trial; anemia; bone marrow suppression; lung non small cell cancer; thrombocytopenia; carcinoma, non-small-cell lung; lung neoplasms; drug administration schedule; continuous infusion; multicenter study; dna topoisomerase inhibitor; erythrocyte transfusion; catheter infection; infusions, intravenous; intravenous drug administration; non-small-cell lung cancer; dna topoisomerases, type i; infusion pumps; phase ii trials; humans; human; male; female; article |
| Journal Title: | American Journal of Clinical Oncology |
| Volume: | 21 |
| Issue: | 5 |
| ISSN: | 0277-3732 |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 1998-10-01 |
| Start Page: | 438 |
| End Page: | 441 |
| Language: | English |
| DOI: | 10.1097/00000421-199810000-00003 |
| PUBMED: | 9781595 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 12 December 2016 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work